Fate Therapeutics Inc (FATE)
3.91
-0.23
(-5.56%)
USD |
NASDAQ |
May 17, 16:00
3.91
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Enterprise Value: 60.40M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 60.40M |
| May 16, 2024 | 87.72M |
| May 15, 2024 | 99.11M |
| May 14, 2024 | 96.83M |
| May 13, 2024 | 88.86M |
| May 10, 2024 | 80.89M |
| May 09, 2024 | 60.40M |
| May 08, 2024 | 37.64M |
| May 07, 2024 | 58.13M |
| May 06, 2024 | 96.83M |
| May 03, 2024 | 78.62M |
| May 02, 2024 | 83.17M |
| May 01, 2024 | 81.97M |
| April 30, 2024 | 66.04M |
| April 29, 2024 | 76.28M |
| April 26, 2024 | 48.96M |
| April 25, 2024 | 56.93M |
| April 24, 2024 | 105.87M |
| April 23, 2024 | 133.19M |
| April 22, 2024 | 160.50M |
| April 19, 2024 | 161.64M |
| April 18, 2024 | 190.10M |
| April 17, 2024 | 216.27M |
| April 16, 2024 | 228.79M |
| April 15, 2024 | 258.39M |
| Date | Value |
|---|---|
| April 12, 2024 | 273.18M |
| April 11, 2024 | 293.67M |
| April 10, 2024 | 330.09M |
| April 09, 2024 | 385.86M |
| April 08, 2024 | 380.05M |
| April 05, 2024 | 403.95M |
| April 04, 2024 | 409.64M |
| April 03, 2024 | 414.19M |
| April 02, 2024 | 390.29M |
| April 01, 2024 | 422.16M |
| March 31, 2024 | 451.74M |
| March 28, 2024 | 520.00M |
| March 27, 2024 | 520.00M |
| March 26, 2024 | 465.38M |
| March 25, 2024 | 466.52M |
| March 22, 2024 | 436.93M |
| March 21, 2024 | 530.24M |
| March 20, 2024 | 422.16M |
| March 19, 2024 | 379.49M |
| March 18, 2024 | 383.46M |
| March 15, 2024 | 428.12M |
| March 14, 2024 | 402.32M |
| March 13, 2024 | 443.00M |
| March 12, 2024 | 444.99M |
| March 11, 2024 | 467.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-187.06M
Minimum
Oct 27 2023
10.42B
Maximum
Jan 14 2021
2.482B
Average
1.689B
Median
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 2.983B |
| Sarepta Therapeutics Inc | 12.27B |
| ADMA Biologics Inc | 2.220B |
| Ocular Therapeutix Inc | 539.23M |
| Viking Therapeutics Inc | 6.425B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.00M |
| Revenue (Quarterly) | 1.925M |
| Total Expenses (Quarterly) | 52.99M |
| EPS Diluted (Quarterly) | -0.47 |
| Profit Margin (Quarterly) | -2.49K% |
| Earnings Yield | -49.23% |
| Normalized Earnings Yield | -49.23 |